These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20693846)

  • 1. Myeloid-derived suppressor cells in human cancer.
    Nagaraj S; Gabrilovich DI
    Cancer J; 2010; 16(4):348-53. PubMed ID: 20693846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
    Fujimura T; Mahnke K; Enk AH
    J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of myeloid-derived suppressor cells.
    Ugel S; Delpozzo F; Desantis G; Papalini F; Simonato F; Sonda N; Zilio S; Bronte V
    Curr Opin Pharmacol; 2009 Aug; 9(4):470-81. PubMed ID: 19616475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
    Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
    Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis.
    Ye XZ; Yu SC; Bian XW
    J Genet Genomics; 2010 Jul; 37(7):423-30. PubMed ID: 20659706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-derived suppressor cell heterogeneity in human cancers.
    Solito S; Marigo I; Pinton L; Damuzzo V; Mandruzzato S; Bronte V
    Ann N Y Acad Sci; 2014 Jun; 1319():47-65. PubMed ID: 24965257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2.
    Zhang Y; Liu Q; Zhang M; Yu Y; Liu X; Cao X
    J Immunol; 2009 Mar; 182(6):3801-8. PubMed ID: 19265159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.
    Lizée G; Radvanyi LG; Overwijk WW; Hwu P
    Clin Cancer Res; 2006 Aug; 12(16):4794-803. PubMed ID: 16914564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the armament and appearances of human myeloid-derived suppressor cells.
    Poschke I; Kiessling R
    Clin Immunol; 2012 Sep; 144(3):250-68. PubMed ID: 22858650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cell role in tumor-related inflammation.
    Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
    Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses in hepatocellular carcinoma.
    Korangy F; Höchst B; Manns MP; Greten TF
    Dig Dis; 2010; 28(1):150-4. PubMed ID: 20460904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.
    Lindau D; Gielen P; Kroesen M; Wesseling P; Adema GJ
    Immunology; 2013 Feb; 138(2):105-15. PubMed ID: 23216602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
    Yang R; Cai Z; Zhang Y; Yutzy WH; Roby KF; Roden RB
    Cancer Res; 2006 Jul; 66(13):6807-15. PubMed ID: 16818658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.
    Tadmor T; Attias D; Polliack A
    Br J Haematol; 2011 Jun; 153(5):557-67. PubMed ID: 21477210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.
    Huang B; Lei Z; Zhao J; Gong W; Liu J; Chen Z; Liu Y; Li D; Yuan Y; Zhang GM; Feng ZH
    Cancer Lett; 2007 Jul; 252(1):86-92. PubMed ID: 17257744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.
    Mandruzzato S; Solito S; Falisi E; Francescato S; Chiarion-Sileni V; Mocellin S; Zanon A; Rossi CR; Nitti D; Bronte V; Zanovello P
    J Immunol; 2009 May; 182(10):6562-8. PubMed ID: 19414811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of tyrosine kinase inhibitors in tumor immunology.
    Nishioka Y; Aono Y; Sone S
    Immunotherapy; 2011 Jan; 3(1):107-16. PubMed ID: 21174561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
    Sinha P; Clements VK; Ostrand-Rosenberg S
    Cancer Res; 2005 Dec; 65(24):11743-51. PubMed ID: 16357187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
    Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
    Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of anti-cancer immunity by regulatory T cells: back to the future.
    Orentas RJ; Kohler ME; Johnson BD
    Semin Cancer Biol; 2006 Apr; 16(2):137-49. PubMed ID: 16376101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.